Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot study

29 Aug 2025

Abstract excerpt

Chronic myeloid leukemia (CML) is a hematologic malignancy originating from hematopoietic stem cells and driven by the BCR-ABL fusion oncogene. Imatinib (IM), a tyrosine kinase inhibitor, is commonly used as a frontline therapy for CML. However, some patients exhibit primary resistance or show persistent molecular evidence of disease despite treatment. Emerging studies indicate that exosome-derived microRNAs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Extracellular vesicles in disease
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40880391
DOI: 10.1371/journal.pone.0331479

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exosomal miRNA expression profiling in patients with imatinib resistant Chronic myeloid leukemia: A pilot studyPMID 40880391Read ↗

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutationsSemantic proximity Read ↗

Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinibSemantic proximity Read ↗

The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)Semantic proximity Read ↗

miRNAs in chronic myeloid leukemia: small molecules, essential functionSemantic proximity Read ↗

microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemiaSemantic proximity Read ↗

Selective miRNA Expression Profile in Chronic Myeloid Leukemia K562 Cell-derived ExosomesSemantic proximity Read ↗

Non-Coding RNAs Are Implicit in Chronic Myeloid Leukemia Therapy ResistanceSemantic proximity Read ↗

The role of microRNAs in the development, progression and drug resistance of chronic myeloid leukemia and their potential clinical significanceSemantic proximity Read ↗

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemiaSemantic proximity Read ↗

MicroRNA ‐based therapies: Revolutionizing the treatment of acute myeloid leukemiaSemantic proximity Read ↗

MicroRNA signature refine response prediction in CMLSemantic proximity Read ↗

MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.